Deal Watch: Immuno-Oncology Collaborations Keep Piling Up
Executive Summary
AstraZeneca and Genentech sign agreements with a number of firms with promising early stage assets, with Bristol looking to spread reach into rare cancers; J&J joins the game. Drama continues to unfold for Mylan/Perrigo, Shire/Baxalta and Horizon/Depomed.